Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis

Taro Pharmaceuticals

Status and phase: Completed; Phase 3

Conditions: Plaque Psoriasis

Treatments: Drug: DSXS; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT02618759

DSXS 1505

Details and patient eligibility

About

The purpose of this study is to evaluate the therapeutic efficacy and safety of DSXS compared to a Placebo (vehicle) in patients with mild to moderate plaque psoriasis.

Full description

To evaluate the therapeutic efficacy and safety of dsxs topical spray, 0.15% (Taro Pharmaceuticals, U.S.A., Inc.) compared to a Placebo (vehicle) spray (Taro Pharmaceuticals, U.S.A., Inc.) in patients with mild to moderate plaque psoriasis.

Enrollment: 119 patients

Sex: All

Ages: 12+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• male and non-pregnant females, 12 years of age or older, with a confirmed diagnosis of mild to moderate plaque psoriasis

Exclusion criteria

• patient is< 12 years old.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

119 participants in 2 patient groups, including a placebo group

DSXS1505

Experimental group

Description:

To evaluate the therapeutic efficacy and safety of DSXS topical spray, 0.15%.

Treatment:

Drug: Placebo

Drug: DSXS

Placebo

Placebo Comparator group

Description:

Eligible patients will be randomized in a 1:1 ratio to Test or Placebo product.

Treatment:

Drug: Placebo

Drug: DSXS